When developing an appropriate outcome for a 15-year-old

1. Crawford ED. Epidemiology of prostate cancer. Urology. 2003;62(6 suppl 1):3–12. [PubMed] [Google Scholar]

2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66. [PubMed] [Google Scholar]

3. Scardino FT. Early detection of prostate cancer. Urol Clin North Am. 1989;16:635–655. [PubMed] [Google Scholar]

4. Speight JL, Roach M. New techniques and management options for localized prostate cancer. Rev Urol. 2006;8(suppl 2):S22–S29. [PMC free article] [PubMed] [Google Scholar]

5. American Cancer Society, authors. Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society; 2007. [Google Scholar]

6. The Department of Defense Center for Prostate Disease Research, authors. Oncology (Williston Park) 1999;13:1336–1336. [PubMed] [Google Scholar]

7. Newcomer LM, Stanford JL, Blumenstein BA, et al. Temporal trends in rates of prostate cancer: declining incidence of advanced stage disease, 1974 to 1994. J Urol. 1997;158:1127–1130. [PubMed] [Google Scholar]

8. Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol. 1990;143:742–746. [PubMed] [Google Scholar]

9. Scher HI, Isaacs JT, Zelefsky MJ, et al. Prostate cancer. In: Abeloff MD, Armitage JO, Lichter AS, et al., editors. Clinical Oncology. 2nd ed. New York, NY: Churchill Livingstone; 2000. pp. 1823–1884. [Google Scholar]

10. Johansson JE, Holmberg L, Johansson S, et al. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA. 1997;277:467–471. [PubMed] [Google Scholar]

11. Ruchlin HS, Pellissier JM. An economic overview of prostate carcinoma. Cancer. 2001;92:2796–2810. [PubMed] [Google Scholar]

12. Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;33:242–248. [PubMed] [Google Scholar]

13. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280:975–980. [PubMed] [Google Scholar]

14. Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005;293:2095–2101. [PubMed] [Google Scholar]

15. Menon M, Parulkar BG, Baker S. Should we treat localized prostate cancer? An opinion. Urology. 1995;46:607–616. [PubMed] [Google Scholar]

16. Krahn MD, Bremner KE, Asaria J, et al. The ten-year rule revisited: accuracy of clinicians’ estimates of life expectancy in patients with localized prostate cancer. Urology. 2002;60:258–263. [PubMed] [Google Scholar]

17. Samet J, Hunt WC, Key C, et al. Choice of cancer therapy varies with age of patient. JAMA. 1986;255:3385–3390. [PubMed] [Google Scholar]

18. Lu-Yao GL, McLerran D, Wasson J, Wennberg JE. An assessment of radical prostatectomy. Time trends, geographic variation, and outcomes. The Prostate Patient Outcomes Research Team. JAMA. 1993;269:2633–2636. [PubMed] [Google Scholar]

19. Sverson RK, Montie JE, Porter AT, Demers RY. Recent trends in incidence and treatment of prostate cancer among elderly men. J Natl Cancer Inst. 1995;87:532–534. [PubMed] [Google Scholar]

20. Desch CE, Penberthy L, Newschaffer CJ, et al. Factors that determine the treatment for local and regional prostate cancer. Med Care. 1996;34:152–162. [PubMed] [Google Scholar]

21. Goodwin JS, Hunt WC, Samet JM. Determinants of cancer therapy in elderly patients. Cancer. 1993;72:594–601. [PubMed] [Google Scholar]

22. Harlan LC, Potosky A, Gilliland FD, et al. Factors associated with initial therapy for clinically localized prostate cancer: Prostate Cancer Outcome Study. J Natl Cancer Inst. 2001;93:1864–1871. [PubMed] [Google Scholar]

23. Bennett CL, Greenfield S, Aronow H, et al. Patterns of care related to age of men with prostate cancer. Cancer. 1991;67:2633–2641. [PubMed] [Google Scholar]

24. Post PN, Kil PJM, Hendrikx AJM, et al. Comorbidity in patients with prostate cancer and its relevance to treatment choice. BJU Int. 1999;84:652–656. [PubMed] [Google Scholar]

25. Yan Y, Carvalhal GF, Catalona WJ, Young JD. Primary treatment choices for men with clinically localized prostate carcinoma detected by screening. Cancer. 2000;88:1122–1130. [PubMed] [Google Scholar]

26. Klotz L. Active surveillance versus radical treatment for favorable-risk localized prostate cancer. Curr Treat Options Oncol. 2006;7:355–362. [PubMed] [Google Scholar]

27. Klotz LH, Nam RK. Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a ‘number needed to treat’ analysis. Can J Urol. 2006;13(suppl 1):48–55. [PubMed] [Google Scholar]

28. Sooriakumaran P, Khaksar SJ, Shah J. Management of prostate cancer. Part 2: localized and locally advanced disease. Expert Rev Anticancer Ther. 2006;6:595–603. [PubMed] [Google Scholar]

29. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE) J Urol. 2003;170(6 Pt 2):S21–S25. discussion S26–S27. [PubMed] [Google Scholar]

30. Gomella LG. Addressing the needs of the high-risk prostate cancer patient. Rev Urol. 2005;7(suppl 5):S18–S28. [PMC free article] [PubMed] [Google Scholar]

31. Horan AH, McGehee M. Mean time to cancer-specific death of apparently clinically localized prostate cancer: policy implications for threshold ages in prostate-specific antigen screening and ablative therapy. BJU Int. 2000;85:1063–1066. [PubMed] [Google Scholar]

32. Minino AM, Smith BL. Deaths: preliminary data for 2000. Natl Vital Stat Rep. 2001;49:1–40. [PubMed] [Google Scholar]

33. Wasson JH, Cushman CC, Bruskewitz RC, et al. for the Prostate Disease Patient Outcome Research Team, authors. A structured literature review of treatment for localized prostate cancer. Arch Fam Med. 1993;2:487–493. [PubMed] [Google Scholar]

34. Johansson JE. Expectant management of early stage prostatic cancer: Swedish experience. J Urol. 1994;152:1753–1756. [PubMed] [Google Scholar]

35. Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368–374. [PubMed] [Google Scholar]

36. Humphrey PA, Keetch DW, Smith DS, et al. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol. 1996;155:816–820. [PubMed] [Google Scholar]

37. Barry MJ, Fleming C, Coley CM, et al. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part IV: estimating the risks and benefits of an early detection program. Urology. 1995;46:445–461. [PubMed] [Google Scholar]

38. Ross KS, Carter HB, Pearson JD, et al. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection. JAMA. 2000;284:1399–1405. [PubMed] [Google Scholar]

39. Carter HB, Landis PK, Metter EJ, et al. Prostate-specific antigen testing of older men. J Natl Cancer Inst. 1999;91:1733–1737. [PMC free article] [PubMed] [Google Scholar]

40. Berger AP, Deibl M, Strasak A, et al. Relapse after radical prostatectomy correlates with preoperative PSA velocity and tumor volume: results from a screening population. Urology. 2006;68:1067–1071. [PubMed] [Google Scholar]

41. D’Amico AV, Hui-Chen M, Renshaw AA, et al. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol. 2006;176(6 Pt 2):S11–S15. [PubMed] [Google Scholar]

42. Yoshino T, Shiina H, Urakami S, et al. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxanebased chemotherapy. Clin Cancer Res. 2006;12(20 Pt 1):6116–6124. [PubMed] [Google Scholar]

43. Alibhai SMH, Krahn MD, Cohen MM, et al. Is there age bias in the treatment of localized prostate carcinoma? Cancer. 2004;100:72–81. [PubMed] [Google Scholar]

44. Schwartz KL, Alibhai SMH, Tomlinson G, et al. Continued undertreatment of older men with localized prostate cancer. Urology. 2003;62:860–865. [PubMed] [Google Scholar]

45. Dahm P, Silverstein AD, Weizer AZ, et al. When to diagnose and how to treat prostate cancer in the “not too fit” elderly. Crit Rev Oncol Hematol. 2003;48:123–131. [PubMed] [Google Scholar]

46. Thompson RH, Slezak JM, Webster WS, Lieber MM. Radical prostatectomy for octogenarians: how old is too old? Urology. 2006;68:1042–1045. [PubMed] [Google Scholar]

47. van Tol-Geerdink JJ, Stalmeier PF, van Lin EN, et al. Do patients with localized prostate cancer treatment really want more aggressive treatment? J Clin Oncol. 2006;24:4581–4586. [PubMed] [Google Scholar]

48. Wong YN, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006;296:2683–2693. [PubMed] [Google Scholar]

49. Talcott JA, Rieker P, Clark JA, et al. Patientreported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study. J Clin Oncol. 1998;16:275–283. [PubMed] [Google Scholar]

50. Lu-Yao GL, Albertsen P, Warren J, Yao SL. Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy—a population-based study. Urology. 1999;54:301–307. [PubMed] [Google Scholar]

51. Stanford JL, Feng Z, Hamilton AS, et al. Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The Prostate Cancer Outcomes Study. JAMA. 2000;283:354–360. [PubMed] [Google Scholar]

52. Corral DA, Bahnson RR. Survival of men with clinically localized prostate cancer detected in the eighth decade of life. J Urol. 1994;151:1326–1329. [PubMed] [Google Scholar]

53. Konety BR, Sharp VJ, Verma M, Williams RD Iowa Prostate Cancer Consensus Panel, authors. Practice patterns in screening and management of prostate cancer in elderly men. Urology. 2006;68:1051–1056. [PubMed] [Google Scholar]

54. Stephens RJ, Dearnaley DP, Cowan R, et al. on behalf of all the RT01 collaborators, authors. The quality of life of men with locally advanced prostate cancer during neoadjuvant hormone therapy: data from the Medical Research Council RT01 trial (ISRCTN 47772397) BJU Int. 2006;99:301–310. [PubMed] [Google Scholar]

55. Harle LK, Maggio M, Shahani S, et al. Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin Adv Hematol Oncol. 2006;4:687–696. [PubMed] [Google Scholar]

56. Wright JL, Higano CS, Lin DW. Intermittent androgen deprivation: clinical experience and practical applications. Urol Clin North Am. 2006;33:167–179. [PubMed] [Google Scholar]

57. Brawer MK. Hormonal therapy for prostate cancer. Rev Urol. 2006;8(suppl 2):S35–S47. [PMC free article] [PubMed] [Google Scholar]

58. Opfermann KJ, Lai Z, Essenmacher L, et al. Intermittent hormone therapy in nonmetastatic prostate cancer. Clin Genitourin Cancer. 2006;5:138–143. [PubMed] [Google Scholar]

59. Klotz LH, Herr HW, Morse MJ, Whitmore WF., Jr Intermittent endocrine therapy for advanced prostate cancer. Cancer. 1986;58:2546–2550. [PubMed] [Google Scholar]

60. Goldenberg SL, Bruchovsky N, Gleave ME, et al. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology. 1995;45:839–844. discussion 844–845. [PubMed] [Google Scholar]